Igrelimogene litadenorepvec clinical trials
Also written TILT-123.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses igrelimogene litadenorepvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
TILT Biotherapeutics Ltd. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test igrelimogene litadenorepvec.
- Nov 2026TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaPhase 1 · TILT Biotherapeutics Ltd.
- Dec 2026Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Phase 1 · TILT Biotherapeutics Ltd.
- Mar 2027Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Phase 1/2 · TILT Biotherapeutics Ltd.
Studies
Open first, then newest update. How each study uses igrelimogene litadenorepvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT05222932Written as TILT-123
- Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active, not recruitingPhase 1/2TILT Biotherapeutics Ltd.NCT05271318Written as TILT-123
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 MonotherapyCompletedPhase 1TILT Biotherapeutics Ltd.NCT04695327Written as TILT-123
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaActive, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT06961786Written as TILT-123
- Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerActive, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT06125197Written as TILT-123
- TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced MelanomaCompletedPhase 1TILT Biotherapeutics Ltd.NCT04217473Written as TILT-123
Codes
What other systems call igrelimogene litadenorepvec · ClinicalTrials.gg INT014818
- UNII (FDA) 484TEV85XSIGRELIMOGENE LITADENOREPVECOne source FDA
- NCI Thesaurus C175454Igrelimogene LitadenorepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 484TEV85XS | IGRELIMOGENE LITADENOREPVEC | One source FDA |
| NCI Thesaurus | C175454 | Igrelimogene Litadenorepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.